Leaders of the ACTIV-6 study, featured recently during NIH Collaboratory Grand Rounds, will hold a town hall Wednesday, June 9, to share information about the study with interested stakeholders, including sites and investigators that may want to participate. The leadership team will describe the rationale for ACTIV-6, share an overview of the platform and objectives, and provide information about how to join and contribute to the study.
Contact DCRI-ACTIV6@dm.duke.edu if you would to receive a calendar invitation the event. The town hall will be recorded for those who are unable to attend.
ACTIV-6, part of the NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program, is a platform trial that will test whether several already approved medications can be repurposed for treating symptoms of mild to moderate COVID-19 in nonhospitalized patients.